Treatment patterns for metastatic hormone-sensitive prostate cancer (mHSPC) progressing after up-front docetaxel in combination with androgen deprivation therapy (D-ADT).

被引：1
|
作者：
Barata, Pedro C.
Emamekhoo, Hamid
Mendiratta, Prateek
Gopalakrishnan, Dharmesh
Koshkin, Vadim S.
Tyler, Allison Janine
Ornstein, Moshe Chaim
Grivas, Petros
Gilligan, Timothy D.
Rini, Brian I.
Kyriakopoulos, Christos
Garcia, Jorge A.
机构：
[1] Cleveland Clin, Cleveland, OH USA
[2] Univ Wisconsin, Madison, WI USA
[3] Cleveland Clin Taussig Canc Insitute, Cleveland, OH USA
[4] Univ Wisconsin Carbone Canc Ctr, Madison, WI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.305
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
305
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Additional cycles of docetaxel in combination with androgen deprivation therapy (D-ADT) in metastatic hormone- sensitive prostate cancer (mHSPC): Efficacy and feasibility analysis.
    Aydogdu, Can
    Urban, Florian
    Tamalunas, Alexander
    Berg, Elena
    Goetz, Melanie
    Rodler, Severin
    Unterrainer, Lena
    Heinemann, Volker
    Stief, Christian G.
    Casuscelli, Jozefina
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Additional cycles of docetaxel in combination with androgen deprivation therapy (D-ADT) in metastatic hormone- sensitive prostate cancer (mHSPC): Efficacy and feasibility analysis.
    Aydogdu, Can
    Urban, Florian
    Tamalunas, Alexander
    Berg, Elena
    Tz, Melanie Go Spacing Diaeresis
    Rodler, Severin
    Heinemann, Volker
    Stief, Christian
    Casuscelli, Jozefina
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [3] Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    Ito, Tetsuro
    Grant, Laura
    Duckham, Bryony R.
    Ribbands, Amanda J.
    Gater, Adam
    ADVANCES IN THERAPY, 2018, 35 (12) : 2186 - 2200
  • [4] Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    Tetsuro Ito
    Laura Grant
    Bryony R. Duckham
    Amanda J. Ribbands
    Adam Gater
    Advances in Therapy, 2018, 35 : 2186 - 2200
  • [5] Comparative efficacy and cost-effectiveness of maximum androgen blockade (MAB), docetaxel with androgen deprivation therapy (ADT), and ADT alone for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in China
    Jiang, W.
    Qu, S.
    Liu, Y.
    Yao, X.
    Liu, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 276 - 276
  • [6] ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC).
    Armstrong, Andrew J.
    Szmulewitz, Russell Zelig
    Petrylak, Daniel Peter
    Holzbeierlein, Jeffrey M.
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris Yakovlevich
    Iguchi, Taro
    Shore, Neal D.
    Rosbrook, Brad
    Baron, Benoit
    Chen, Lucy F.
    Stenzl, Arnulf
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Early Docetaxel and Androgen Deprivation in the Treatment of Metastatic, Hormone-sensitive Prostate Cancer
    Tassinari, Davide
    Tamburini, Emiliano
    Gianni, Lorenzo
    Drudi, Fabrizio
    Fantini, Manuela
    Santelmo, Carlotta
    Stocchi, Lucia
    Montanari, Francesco
    Sartori, Sergio
    REVIEWS ON RECENT CLINICAL TRIALS, 2016, 11 (04) : 317 - 323
  • [8] Dosing, safety, and pharmacokinetics (PK) of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the ARASENS study
    Kalebasty, Arash Rezazadeh
    Hammerer, Peter
    Tombal, Bertrand
    Hussain, Maha
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, David
    Zhang, Weijiang
    Ploeger, Bart
    Li, Rui
    Kuss, Iris
    Zieschang, Carsten
    Wittemer-Rump, Sabine
    Smith, Mathew
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 80 - 81
  • [9] Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis
    Tan, Pui San
    Aguiar Jr, Pedro
    Haaland, Benjamin
    Lopes, Gilberto
    PROSTATE CANCER AND PROSTATIC DISEASES, 2018, 21 (04) : 516 - 523
  • [10] EFFICACY AND FEASIBILITY OF ADDITIONAL CYCLES OF DOCETAXEL IN COMBINATION WITH ANDROGEN DEPRIVATION THERAPY IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
    Aydogdu, Can
    Urban, Florian
    Tamalunas, Alexander
    Berg, Elena
    Goetz, Melanie
    Rodler, Severin
    Heinemann, Volker
    Stief, Christian G.
    Casuscelli, Jozefina
    JOURNAL OF UROLOGY, 2023, 209 : E388 - E389
12345